Starling Oncology, Inc.
NASDAQStarling Oncology enters the final week of August with an unusual divergence: the stock has pulled back nearly 5% over the week to $6.17, yet the dominant insider in the register has spent the past three months buying every meaningful dip. The most striking feature of the current setup is the persistence of insider accumulation from the company's largest shareholder. Jorey…
Snapshot as of 22 Sept 2026
Starling Oncology enters the final week of August with an unusual divergence: the stock has pulled back nearly 5% over the week to $6.17, yet the dominant insider in the register has spent the past three months buying…
STLN has already delivered one of the sharpest single-session moves in its recent history — and the market is about to ask it to do it again. The stock closed at $6.39 on August 7, up 28% in one day and 31% on the…
STLN heads into its August 11 earnings report on the back of a sharp, sudden re-rating — and the data tells a story of bullish conviction without much short-side resistance. The stock gained 28% in a single session on…
The Oncology Institute enters the back half of June with a rare combination: a stock up 28% over the past month, analysts actively raising targets, and a lending market so loose it barely registers as a short thesis at…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for STLN — free to start on ORTEX.
Sign up for free →Open STLN on ORTEX